Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul class="summary-list"><li>Airbnb stock fell a record amount after the company reported earnings after the bell on Tuesday. </li><li>The company noted US demand is slowing and that marketing costs are expected to rise. </li></ul><p>Airbnb stock dropped by the most on record on Wednesday as the company reported second-quarter earnings that revealed it is seeing a slowdown in demand from travelers in the US. </p><p>The stock dropped as much as 14% Wednesday morning. It pared some of that loss and was trading 13% lower at $113.49 at 12:45 pm.m ET. </p><p>Airbnb noted that consumers aren't booking as many stays on the site, and also said marketing costs will rise as it looks to invest in new markets. </p><p>Analysts were downbeat on the results, with RBC Capital Markets noting concerns about the marketing costs in particular. </p><p>"Kicking up marketing spend at a moment when demand is softening tends to be the ultimate backbreaker for an internet stock in our experience," analysts from RBC wrote in a Wednesday note.</p><p>In a <a target="_blank" class="" href="https://s26.q4cdn.com/656283129/files/doc_financials/2024/q2/Airbnb_Q2-2024-Shareholder-Letter_Final.pdf">letter to shareholders</a>, Airbnb's executives said they're "seeing shorter booking lead times globally and some signs of slowing demand from U.S. guests," joining other big companies to that have warned consumer spending is drying up, including McDonalds and Amazon.</p><p>They added that Airbnb's marketing costs will likely outpace revenue growth in the next quarter.</p><p>"Marketing expense is expected to grow faster than revenue on a year-over-year basis in Q3 2024, partially due to timing and investments in new growth markets," they wrote.</p><p>Analysts from Bank of America said Airbnb remains the top competitor in alternative accommodation, but growth in the sector is slowing as the post-pandemic travel surge weakens. There's a risk that competition will further drive up Airbnb's marketing spend, they added.</p><p>"We continue to favor gig economy over Online travel as reopening benefits fade," the analysts wrote.</p><p>Airbnb's revenue for the most recent quarter increased 11% year-over-year, but earnings missed estimates. Net income fell 15%, and earnings per share came in at $0.86 cents, falling short of analyst expectations of $0.92 cents, according to LSEG data.</p><p>The earnings miss comes as other companies <span>have also warned of slowing consumer spending in recent earnings reports. McDonald's saw its global comparable sales fall 1% year-over-year last quarter and is now </span><a target="_blank" href="https://markets.businessinsider.com/news/stocks/mcdonalds-stock-price-soaring-big-q2-earnings-miss-value-meals-2024-7"><span>focusing on</span></a><a target="_blank" class="" href="https://markets.businessinsider.com/news/stocks/mcdonalds-stock-price-soaring-big-q2-earnings-miss-value-meals-2024-7"> its $5 value meals </a>to get customers back in the door.</p><p>And Brian Olsavsky, Amazon's chief financial officer, told reporters last week that consumers "are continuing to be cautious with their spending," and that people are on the hunt for deals.</p>

An 'ultimate backbreaker' sparked a record plunge in Airbnb stock after earnings

<p></p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div><p></p></div></div>T-Mobile is coming under fire online after CEO John Legere attacked civil liberties group EFF (Electronic Frontier Foundation) in a foul-mouthed rant.<p>The row comes after <a href="https://www.eff.org/deeplinks/2016/01/eff-confirms-t-mobiles-bingeon-optimization-just-throttling-applies">the EFF accused T-Mobile of violating Net Neutrality</a> - the principle that all data must be treated equally.</p><p>"Who the f--- are you, anyway, EFF?" Legere asked. "Why are you stirring up so much trouble, and who pays you?"</p><p>In response, many internet users have supported the group and attacked T-Mobile, using the hashtag #WeAreEFF.</p><p>The heart of the issue is "Binge On," a new service T-Mobile offers. It lets video data from certain companies not count towards users' monthly data cap, leaving them free to watch much more video content. <a href="https://www.eff.org/deeplinks/2016/01/eff-confirms-t-mobiles-bingeon-optimization-just-throttling-applies">But according to tests run by the EFF</a>, it throttles all video content it can detect to the speed of 1.5Mps, "even when the phone is capable of downloading at higher speeds, and regardless of whether or not the video provider enrolled in Binge On."</p><p>Combined with the fact it "zero rates" some data, meaning it doesn't contribute to user limits, this is arguably a violation of net neutrality, which stipulates that carriers cannot discriminate against or preferentially treat any types of data - it all has to be treated equally. Net Neutrality is now part and parcel of FCC regulations in the US, so if T-Mobile is violating them, it could face consequences.</p><p>T-Mobile is already due to meet with the FCC to discuss zero rating, and <a href="http://arstechnica.com/business/2016/01/t-mobiles-video-throttling-may-not-violate-net-neutrality-lawyers-say/">there's some debate as to whether or not the company's actions technically violate net neutrality</a>.</p><p>But in responding to recent criticisms, John Legere has raised the ire of many internet activists. On Thursday, he published a video on YouTube claiming to "set the record straight" about Binge On, framing it as about "customer choice."</p><p><div></div></p><p class="embed-spacer">The CEO then followed it up with a Q&amp;A session on Twitter, in which he recorded a selfie-message targeting the EFF.</p><p class="embed-spacer"><div></div></p><p>EFF asked: "Does Binge On alter the video stream in any way, or just limit its bandwidth?"</p><p>To which Legere responded: "So what Binge On does, it includes a proprietaty technology and what the technology does is not only detect the video stream but also select the bitrate to optimise to the mobile device. That's part A of my answer. Part B of my answer is: Who the f--- are you, anyway, EFF? Why are you stirring up so much trouble, and who pays you?"</p><p class="embed-spacer">People immediately questioned the wisdom of pitting a mobile carrier against a very well-regarded civil liberties group with decades of activism under its belt:</p><p class="embed-spacer"><div></div></p><p class="embed-spacer">Twitter users subsequently rallied in support of EFF, using #WeAreEFF as a banner.</p><p><div></div></p><p class="embed-spacer"><div></div></p><p class="embed-spacer"><div></div></p><p class="embed-spacer"><div></div></p><p class="embed-spacer"><div></div></p><p>Legere has since struck a reconcilliatory tone - acknowledging that the EFF does "a lot of great things for a lot of consumers," but that "innovation can be controversial!"</p><p class="embed-spacer"><div></div></p><p class="embed-spacer"><div></div></p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/south-koreans-tech-watching-people-eat-online-mukbang-2015-12">This 14-year-old makes up to $1,500 a night eating dinner in front of a webcam in South Korea</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="MwMDZkdzr7V54pSPAwMT1JU7p7MqmuY1" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

The CEO of T-Mobile got in a fight with a rights group over claims his company is throttling customers' data

<p></p><div class="KonaFilter image-container display-table"><div><div class="image on-image"></div><p></p></div></div><ul class="summary-list"><li><a href="https://www.linkedin.com/in/ethan-perlstein-1260545">Ethan Perlstein</a> started the biotech <a href="https://www.perlara.com">Perlara</a> to focus on developing treatments for patients with devastating rare diseases who don't currently have options.</li><li>In five years, Perlara quickly vaulted to success, from a slot in <a href="https://www.ycombinator.com/">Y Combinator</a> to investments from drug giant <a href="https://www.novartis.com/">Novartis</a> and the billionaire Mark Cuban.&#xa0;</li><li>But when things went south, Perlstein was forced to wind down the business.</li><li>He told Business Insider about how he built a biotech from scratch as a first-time entrepreneur, and what went wrong.&#xa0;</li><li><a href="https://www.businessinsider.com/?hprecirc-bullet">Visit Business Insider's homepage for more stories.</a></li></ul><p><a href="https://www.linkedin.com/in/ethan-perlstein-1260545">Ethan Perlstein</a> never meant to become an entrepreneur.&#xa0;</p><p>"I became a biotech entrepreneur out of necessity," he says.</p><p>The Harvard- and Princeton-trained scientist was following a path to academia when, by his own telling, academia wouldn't have him.&#xa0;</p><p></p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div><p></p></div></div><p>So the 39-year-old chose to start his own biotech company, which he likes to joke is much safer and not at all risky.</p><p>In 2014, Perlstein started <a href="https://www.perlara.com">Perlara</a>, basing it in Oakland, California. Focusing on treatments for devastating rare diseases, Perlara saw some initial success.</p><p>In 2016, it <a href="https://www.perlara.com/blog/why-y-combinator/">scored</a>&#xa0;a slot in the startup accelerator&#xa0;<a href="https://www.businessinsider.com/y-combinator-accepted-15000-startups-into-startup-school-2018-8">Y Combinator,</a> which is reportedly&#xa0;more exclusive than Harvard.</p><p>Twitter connected the biotech with rare disease advocates, and helped it catch the eye of the billionaire <a href="https://www.biospace.com/article/shark-tank-billionaire-mark-cuban-invests-in-tiny-bay-area-biotech-perlara/">Mark Cuban</a>, whose Radical Investments fund invested $250,000, plus a similar amount of additional funds towards a specific rare-disease program.</p><p>The Swiss drug giant Novartis also invested in Perlara and formed a <a href="https://www.prnewswire.com/news-releases/perlara-pbc-announces-pharma-collaboration-300347210.html">research partnership</a> with the biotech in 2016.&#xa0;</p><p>In five years, the startup brought in nearly $10 million from investors and $2 million in revenue from research partnerships with patient advocacy groups, and employed 15 full-time workers.</p><h2>How Perlstein started a successful biotech from scratch</h2><p></p><div class="KonaFilter image-container display-table"><div><div class="image on-image"></div><p></p></div></div><p>"It was tenuous, not fully sustainable. But it was working," Perlstein told Business Insider.</p><p>He credits that to the company's work in 12 disease areas, including pancreatitis, mitochondrial disease and some neurodevelopmental conditions. Revenue from those programs helped Perlara be cash-flow positive last year, he said.</p><p><em><strong>Read more: <a href="https://www.businessinsider.com/clinical-trial-startups-raise-1-billion-to-transform-drug-development-2019-4" data-analytics-position="7">Creating a new drug takes a decade and costs a fortune. Investors have poured almost $1 billion into startups trying to change that.</a></strong></em></p><p>Perlara also tried to help patients who might not otherwise be a focus for big pharma companies by finding drugs that were already out there and repurposing them.</p><p>The biotech worked with a family in Michigan, for instance, to find a drug that had been approved outside of the US and might be used to treat the rare inherited condition <a href="https://ghr.nlm.nih.gov/condition/pmm2-congenital-disorder-of-glycosylation#genes">PMM2-CDG.</a> &#xa0;</p><p>Most babies with the deficiency are stillborn or die quickly, and those who survive are affected in a variety of severe ways, including developmentally. It's also incredibly rare: more than 800 people have been identified with it worldwide, according to the <a href="https://ghr.nlm.nih.gov/condition/pmm2-congenital-disorder-of-glycosylation#statistics">NIH</a>.</p><h2>...and how it all went wrong</h2><p></p><div class="KonaFilter image-container display-table"><div><div class="image on-image"></div><p></p></div></div>But then Perlara's model hit a wall. The company had grown too quickly, and a longtime partner suddenly walked out of a negotiation, sparking a tailspin in January 2019, according to Perlstein.&#xa0;<p>Months courting additional funds from <a href="https://www.businessinsider.com/career-advice-from-biotech-venture-capital-veteran-wende-hutton-2018-2">seasoned biotech VCs,</a>&#xa0;<a href="https://www.businessinsider.com/57-tech-startups-vc-insiders-say-will-boom-in-2019-2019-1">tech VCs,</a> and institutional investors didn't pan out.&#xa0;<span style="font-weight: 400;"></span></p><p>&#xa0;</p><p>Now winding down the company, Perlstein has some thoughts about what went wrong.</p><p>Perlara was formed as a "<a href="https://www.delawareinc.com/blog/non-profit-corporation-vs-public-benefit-corporation/">public benefit corporation</a>," a structure aimed at bringing the values of a nonprofit to the corporate world. Its full name, Perlara PBC, nodded to that difference. But he suspects the PBC structure may have made new investors reluctant to invest.&#xa0;</p><p>And maybe Perlara broke out of the box too much, Perlstein says, varying up its scientific approach, and its platform, and its corporate structure. Maybe it should have stuck closer to the model established by other biotech startups</p><p><em><strong>Never miss out on healthcare news. <a href="http://newsletter.businessinsider.com/join/4np/health-insider&amp;hash=f4e91136c13f3c40c496d77bc7347502">Subscribe to Dispensed</a>, our weekly newsletter on pharma, biotech, and healthcare.</strong></em></p><p>He wouldn't go back and change his decisions, he says. But he would have grown Perlara in a slower way, perhaps by launching six research programs instead of 12, because it put the company in a vulnerable spot when it lost the key partner.&#xa0;</p><p>"Be as idealistic as your heart wants you to be, but know with your brain to make a business, you're going to have to sacrifice one of those dimensions," is Perlstein's advice for <a href="https://www.businessinsider.com/business-advice-entrepreneurs-startup-founders-ceos-2018-5">other young founders.</a></p><p>And having public support is great, crucial even, "but at the end of the day, it doesn't change the number in the bank account," he said.&#xa0;</p><p><em><strong>Read more: <a href="https://www.businessinsider.com/biogen-earnings-stock-price-after-aducanumab-alzheimers-failure-mizuhos-salim-syed-2019-4" data-analytics-position="1">Biogen has seen $19 billion wiped out since a promising drug flopped - and one analyst has a bold idea for how the biotech pioneer can recover</a></strong></em></p><div></div>    <div class="margin-top">        <h3>NOW WATCH: <a href="https://www.businessinsider.com/donald-trump-airline-shuttle-transportation-pan-am-eastern-new-york-2019-1">The rise and fall of Donald Trump's $365 million airline</a></h3>        <div>                    </div>    </div>

The buzzy biotech Perlara got into Y Combinator and raised $10 million from investors like Mark Cuban before things went south. Its founder shares the key lesson he learned from the failure.

<p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"><p class="source"><span>Kimberly White / Getty Images</span></p><p class="caption">23andMe cofounder Anne Wojcicki.</p></div><p></p></div></div></p><p>The personal genomics company <a href="https://www.23andme.com/">23andMe</a> has officially resumed a service that tells curious customers about what lurks in their DNA, including some inheritable health risks.</p><p>The move comes nearly two years after the US Food and Drug Administration (FDA) sent 23andMe <a href="http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm">a strongly worded warning letter,</a> effectively shutting down the health-related aspects of the company's popular DNA reports.</p><p>After working closely with the FDA, however, 23andMe is again offering health information. <strong>The company and its CEO are billing the rebooted genetic testing service, announced Wednesday, Oct. 21, as "a totally new experience."</strong></p><p>It's a major turnaround from where the tech startup was November 2013.</p><p>Back then, the FDA <a href="http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm">noted</a> 23andMe was providing "health reports on 254 diseases and conditions." Those included genetic risk assessments for complex, serious diseases like breast cancer and diabetes. After many conversations and meetings with 23andMe, an FDA deputy commissioner <a href="http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm">wrote</a>, "we still do not have any assurance that the firm has analytically or clinically validated the [Personal Genome Service] for its intended uses."</p><p>The new offerings from 23andMe, which cost $199 (<a href="http://www.scientificamerican.com/article/23andme-is-terrifying-but-not-for-reasons-fda/">twice the price of its old test</a>) are significantly more limited - and regulated. No one will learn about a very serious disease or the risk of one from these results, lowering the stakes considerably.</p><p>But there are 60 pieces of information in each report, including details about a customer's carrier status for certain diseases, a profile of certain hereditary traits (e.g. "back hair" and "sweet taste preference"), and limited information about certain non-life-threatening health conditions like lactose intolerance. (See the full list <a href="#below">below</a>).</p><p>"It's a totally different type of report," 23andMe CEO and biologist Anne Wojcicki told Tech Insider. "We've established an infrastructure with the FDA, where we know that people understand it. We have comprehension levels of over 90%. We're confident people from all educational backgrounds can understand this information." As a result of collaborating with the FDA, Wojcicki said in a statement, "we are a better company with a better product."</p><p>Already, in February 2015, the FDA signaled that they were coming around on the company. That's when the agency <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435003.htm">approved</a> a 23andMe test that could show whether someone was a carrier for a rare genetic disorder called <a href="http://ghr.nlm.nih.gov/condition/bloom-syndrome">Bloom syndrome</a>.</p><p>At the same time, the FDA reclassified the carrier tests for similar genetic diseases so that companies marketing them did not need to seek review before doing so. The move "supports innovation and will ultimately benefit consumers," an FDA official said at the time, in <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435003.htm">a statement</a>.</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>Pelle Sten / Flickr</span></p><p class="caption">An old 23andMe testing kit.</p></div><p></p></div></div></p><p>Getting knocked down by the FDA wasn't easy, says Wojcicki - especially since 23andMe now has to meet much more rigorous FDA standards, which are normally applied to medical devices. But she believes 23andMe's reincarnation has put the entire tech industry in a better place.</p><p>"The FDA has made a spectacular effort in the last year to understand Silicon Valley" while also helping health startups meet regulations, she says. "Part of what I see as my role now, as being known in the industry for 'the smackdown,' is helping other companies understand what that process looks like and having realistic expectations."</p><p>Still, 23andMe's rebooted service doesn't yet offer its former, more complete dump of health information hidden in a customer's DNA. And that pains Wojcicki.</p><p>"I'd be very disappointed if I could not at some point get there," she says.</p><p>Not everyone is sold on the idea though. As Davey Alba wrote in <a href="http://www.wired.com/2015/01/23andme-partners-big-pharma-find-treatments-hidden-genes/">Wired</a>, even when 23andMe couldn't offer its signature health reports, it still held onto "one of its most valuable assets" - its customers' genetic data. That's led to some <a href="http://www.nytimes.com/roomfordebate/2015/03/02/23andme-and-the-promise-of-anonymous-genetic-testing-10/23andmes-dangerous-business-model-17">concerns about privacy</a>. "The Personal Genome Service isn't primarily intended to be a medical device," Charles Seife <a href="http://www.scientificamerican.com/article/23andme-is-terrifying-but-not-for-reasons-fda/">argued in Scientific American</a>. "It is a mechanism meant to be a front end for a massive information-gathering operation against an unwitting public."</p><p>Wojcicki rejects these criticisms. She says about 80% of customers volunteer to participate in research and share their anonymized genomic data with researchers, including <a href="http://www.forbes.com/sites/matthewherper/2015/01/06/surprise-with-60-million-genentech-deal-23andme-has-a-business-plan/">several pharma giants</a>, and that the company has always been "extremely transparent" about this. Such partnerships have the potential to lead to some compelling information about diseases, and even possibly some new treatments.</p><p>"If 5,000 people with chronic fatigue syndrome say, 'screw it, we don't just want to wait around for treatment anymore,'" Wojcicki says, "well, then they actually have the power to come together and generate data together and use that in analyses and actually start to learn form each other."</p><p>With the relaunch of its genetic reports - which expand significantly on the ancestry information provided by other companies - 23andMe sets itself apart from the crowd, once again directly offering consumers something they can't get anywhere else.</p><p>And the reverse is true, too: 23andMe has troves of unprecedented genomic data.</p><p>"We are not a profitable company. We are doing deals because we feel it's the right thing to do to make a difference in the research world," Wojcicki says. "We are trying to show that there can be a consumer-driven research model that rivals - and potentially could be even be better than - the existing, academic-led, government-funded research model."</p><p><a name="below"></a></p><p>Here's the full list of what's in the new reports:</p><p><strong>Carrier Status (36)</strong></p><p style="padding-left: 30px;">ARSACS</p><p style="padding-left: 30px;">Agenesis of the Corpus Callosum with Peripheral Neuropathy</p><p style="padding-left: 30px;">Autosomal Recessive Polycystic Kidney Disease</p><p style="padding-left: 30px;">Beta Thalassemia and Related Hemoglobinopathies</p><p style="padding-left: 30px;">Bloom Syndrome</p><p style="padding-left: 30px;">Congenital Disorder of Glycosylation Type 1a (PMM2-CDG)</p><p style="padding-left: 30px;">Cystic Fibrosis</p><p style="padding-left: 30px;">D-Bifunctional Protein Deficiency</p><p style="padding-left: 30px;">Dihydrolipoamide Dehydrogenase Deficiency</p><p style="padding-left: 30px;">Familial Dysautonomia</p><p style="padding-left: 30px;">Fanconi Anemia Group C</p><p style="padding-left: 30px;">GRACILE Syndrome</p><p style="padding-left: 30px;">Glycogen Storage Disease Type Ia</p><p style="padding-left: 30px;">Glycogen Storage Disease Type Ib</p><p style="padding-left: 30px;">Hereditary Fructose Intolerance</p><p style="padding-left: 30px;">Leigh Syndrome, French Canadian Type</p><p style="padding-left: 30px;">Limb-Girdle Muscular Dystrophy Type 2D</p><p style="padding-left: 30px;">Limb-Girdle Muscular Dystrophy Type 2E</p><p style="padding-left: 30px;">Limb-Girdle Muscular Dystrophy Type 2I</p><p style="padding-left: 30px;">MCAD Deficiency</p><p style="padding-left: 30px;">Maple Syrup Urine Disease Type 1B</p><p style="padding-left: 30px;">Neuronal Ceroid Lipofuscinosis (CLN5-Related)</p><p style="padding-left: 30px;">Neuronal Ceroid Lipofuscinosis (PPT1-Related)</p><p style="padding-left: 30px;">Niemann-Pick Disease Type A</p><p style="padding-left: 30px;">Nijmegen Breakage Syndrome</p><p style="padding-left: 30px;">Nonsyndromic Hearing Loss and Deafness, DFNB1 (GJB2-Related)</p><p style="padding-left: 30px;">Pendred Syndrome and DFNB4 Hearing Loss</p><p style="padding-left: 30px;">Primary Hyperoxaluria Type 2</p><p style="padding-left: 30px;">Rhizomelic Chondrodysplasia Punctata Type 1</p><p style="padding-left: 30px;">Sickle Cell Anemia</p><p style="padding-left: 30px;">Sjögren-Larsson Syndrome</p><p style="padding-left: 30px;">Tay-Sachs Disease</p><p style="padding-left: 30px;">Tyrosinemia Type I</p><p style="padding-left: 30px;">Usher Syndrome Type 1F</p><p style="padding-left: 30px;">Usher Syndrome Type 3A</p><p style="padding-left: 30px;">Zellweger Syndrome Spectrum (PEX1-Related)</p><p><strong>Wellness (4)</strong></p><p style="padding-left: 30px;">Caffeine Consumption</p><p style="padding-left: 30px;">Lactose Intolerance</p><p style="padding-left: 30px;">Alcohol Flush Reaction</p><p style="padding-left: 30px;">Muscle Composition</p><p><strong>Traits (22)</strong></p><p style="padding-left: 30px;">Asparagus Odor Detection</p><p style="padding-left: 30px;">Back Hair (available for men only)</p><p style="padding-left: 30px;">Bald Spot (available for men only)</p><p style="padding-left: 30px;">Bitter Taste Perception</p><p style="padding-left: 30px;">Cheek Dimples</p><p style="padding-left: 30px;">Cleft Chin</p><p style="padding-left: 30px;">Earlobe Type</p><p style="padding-left: 30px;">Earwax Type</p><p style="padding-left: 30px;">Eye Color</p><p style="padding-left: 30px;">Finger Length Ratio</p><p style="padding-left: 30px;">Freckles</p><p style="padding-left: 30px;">Hair Curliness</p><p style="padding-left: 30px;">Light or Dark Hair</p><p style="padding-left: 30px;">Male Hair Loss (available for men only)</p><p style="padding-left: 30px;">Newborn Hair Amount</p><p style="padding-left: 30px;">Photic Sneeze Reflex</p><p style="padding-left: 30px;">Red Hair</p><p style="padding-left: 30px;">Skin Pigmentation</p><p style="padding-left: 30px;">Sweet Taste Preference</p><p style="padding-left: 30px;">Toe Length Ratio</p><p style="padding-left: 30px;">Unibrow</p><p style="padding-left: 30px;">Widow's Peak</p><p><strong>Ancestry (3)</strong></p><p style="padding-left: 30px;">Ancestry Composition</p><p style="padding-left: 30px;">Haplogroups</p><p style="padding-left: 30px;">Neanderthal Ancestry</p><p style="padding-left: 30px;"> </p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/how-the-crispr-dna-editing-tool-works-2015-10">Watch science writer Carl Zimmer explain CRISPR in 90 seconds</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="02Z2M0eDoPAy5YuLDPvh7Tg3nC3qY_56" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

You Searched For "pmm" and got 4 results

An 'ultimate backbreaker' sparked a record plunge in Airbnb stock after earnings

Kelly Cloonan

The CEO of T-Mobile got in a fight with a rights group over claims his company is throttling customers' data

Rob Price

The buzzy biotech Perlara got into Y Combinator and raised $10 million from investors like Mark Cuban before things went south. Its founder shares the key lesson he learned from the failure.

Emma Court

23 months after a government 'smackdown,' 23andMe is finally ready to test your DNA again

Lauren F Friedman,Dave Mosher

Popular Keywords

Buying Guides